Hotels allege predatory pricing, forced exclusivity in Trip.com antitrust probe

Trip.com's dominant position (about 56% of China’s online travel market) and frequent discount campaigns are blamed for driving Chinese hotel room rates to levels not seen in over a decade and eroding operator profitability, even as domestic travel rebounds (nearly 5 billion trips in the first three quarters of 2025). Beijing has opened an antitrust probe into Trip.com's exclusive “er xuan yi” arrangements that favor top-tier merchants, a development that has pushed Trip.com shares down more than 16% since the investigation was announced and creates material downside risk for the company and pressure on hotel RevPAR (flat across China in 2025; Marriott China revPAR down ~1% last year).

Analysis

Market structure: Trip.com (56% share) is the monopolistic price-setter in Chinese online travel; exclusivity (“er xuan yi”) concentrates traffic but transfers yield risk to hoteliers, compressing RevPAR (flat in 2025 vs peers) despite ~5bn trips YTD. Winners: rival platforms (Alibaba/Fliggy, Meituan, Douyin) and regulators if exclusivity is curtailed; losers: small operators with thin margins and TCOM’s high-margin commission model.

Risk assessment: Key tail risks include a formal SAMR remedy or fines that force de-listing clauses—this could reduce TCOM EBITDA by an estimated 10–30% over 12 months if commission structures/visibility algorithms change. Near-term (30–90 days) the probe drives volatility and booking-discounting; medium term (3–12 months) expect margin pressure on hotels and possible re-pricing of OTA multiples; long term (>12 months) network effects still favor the largest aggregator unless structural remedies are imposed.

Trade implications: High-conviction trade is short TCOM via limited-risk put spreads or buying volatility (3–6 month tenor) to capture regulatory outcomes; relative-value long exposure to BABA/Meituan captures redistribution of share if exclusivity ends. Trim discretionary/hotel exposure (e.g., MAR) to limit China-RevPAR downside and hedge with short-dated puts sized to China revenue sensitivity.

Contrarian angles: The market may be over-pricing existential risk—Trip.com’s distribution moat and scale mean a partial remedy (fines, minor behavioral remedies) is likelier than structural break-up. If probe outcomes are limited within 90–180 days, a sharp mean-reversion rally of 20–40% is possible; conversely, aggressive remedies could leave TCOM structurally impaired and create long-term winners among rivals.

Key Decisions for Investors

• Establish a 2–3% portfolio short on TCOM using a 3-month put spread (buy 25% OTM, sell 40% OTM) to cap cost; target 30% downside, set stop-loss to unwind if probe cleared with no enforcement within 90 days and TCOM rallies 15%.
• Implement a pair trade: long 2% BABA (or equivalent exposure to Fliggy/Meituan themes) and short 2% TCOM (equal dollar) for 6–12 months to capture potential share reallocation if exclusivity is banned; rebalance at 6 months or on regulatory resolution.
• Reduce exposure to lodging/hospitality (e.g., trim MAR by 1–2%) and purchase 6-month MAR puts ~10% OTM sized to offset ~50% of estimated China EBITDA sensitivity to a 3–6% RevPAR decline.
• Buy a 0.5–1% portfolio-sized 3-month ATM straddle on TCOM (or long-dated call/put combo) to play regulatory-driven IV spikes; exit on regulatory announcement or within 90 days to capture event-driven volatility.